Cannassure Therapeutics Ltd. has signed an exclusive licensing agreement with Lipidor AB. Under the agreement, Cannassure has the exclusive right to use Lipidor's proprietary drug delivery technology AKVANO in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain, and lesions. DanCann Pharma is the exclusive multinational distributor of the Israelian-based company's product portfolio for whole Scandinavia.

The exclusive licensing agreement between Cannassure and Lipidor Under the terms of the agreement, Cannassure shall during the coming years develop products with the goal of entering the market in the non -prescription segment, and later in the prescription segment. Lipidor retains the right to develop cannabis-related products in other indications than those covered by the exclusive licensing agreement. The agreement is valid as long as Lipidor has patent protection of the AKVANO formulation under existing patents or under possible new patents that may arise during the collaboration.

Cannassure assesses, based on public information, that the market for topical therapies for indications under the scope of this license agreement will undergo a significant growth in the next few years and may exceed USD 50 billion by 2027. Cannassure's ambition is to compete successfully in these fields with innovative cannabis products. The Distribution Agreement between DanCann Pharma and Cannassure DanCann Pharma and Cannassure announced back in December 2020 their strategic partnership.

Under the terms of the Distribution Agreement, DanCann Pharma will be the exclusive Scandinavian distributor for the product portfolio from Cannassure, including all Cannassure's products in various formulations and further additional products that Cannassure have in their future pipeline. The Distribution Agreement does not counteract DanCann Pharma's current agreements but creates an even broader product portfolio in terms of dosage, formulation, and delivery of cannabinoid -based pharmaceuticals for DanCann Pharma with the goal of becoming the leading supplier of medical cannabis in Scandinavia. Under the terms of the Distribution Agreement, DanCann Pharma will employ its sales, regulatory, and distribution department, to distribute Cannassure's product portfolio in the Territory.

The specific products, as well as the branding will be determined mutually by both parties. The Distribution Agreement covers both pharmaceuticals for the Rx- and OTC -market. DanCann Pharma will submit its first product approval application to the Danish Medicines Agency for the Distribution Agreement in the beginning of 2021 to have the products approved for the Danish Medical Cannabis Pilot Programme.

The products are expected to produce significant and strong revenues for DanCann Pharma when successfully commercialized.